7 results
Brief Overview of Treatment Agents for COVID-19 - Version 2.01 4/11/2020

#Drugs #Medications #Treatment #COVID19 #Pharmacology #Table
Brief Overview of ... Treatment Agents ... 4/11/2020 #Drugs ... #COVID19 #Pharmacology ... #Table #Management
Overview of antifungal agents benefits, weaknesses, and adverse effects in the treatment of Coccidioidomycosis.
Fluconazole - Low
Overview of antifungal ... tolerable • High MIC ... • Therapeutic drug ... #treatment #antifungals ... #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
chew, or crush tablet ... Note: Systemic antifungals ... mucosal #IDSA #Prevention ... #Treatment #management ... infections #HIVAIDS #pharmacology
It is important to recognize Acute Decompensated Heart Failure (ADHF) as more than just simply a
then placed on prevention ... differential #algorithm #management ... #table #foamed ... #criticalcare #icu ... #clinical #pharmacology
IDSA Recommendations for Preventing and Treating Disseminated Mycobacterium Avium Complex in HIV-AIDS
Preventing 1st Episode of Disseminated
Recommendations for Preventing ... Complex in HIV-AIDS Preventing ... please refer to Table ... #Treatment #management ... infections #HIVAIDS #pharmacology
Antifungal agents benefits, weaknesses, and adverse effects in the treatment of Coccidioidomycosis
Fluconazole
 - Benefits: Low cost/tolerable
Antifungal agents ... Weaknesses: High MIC ... Weaknesses: Therapeutic drug ... Coccidioidomycosis #pharmacology ... #management #treatment
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
Please refer to the table ... below for TB drug ... Tuberculosis #TB #IDSA #Prevention ... #Treatment #management ... infections #HIVAIDS #pharmacology